162 
(B) by adding at the end the following new 
paragraph: 
‘‘(3) CONTINUATION OF OPERATION OF SUB-
COMMITTEE.—Notwithstanding section 14 of the 
Federal Advisory Committee Act, the Subcommittee 
shall continue to operate during the five-year period 
beginning on the date of the enactment of the Best 
Pharmaceuticals for Children Act of 2007.’’; and 
(2) in subsection (d), by striking ‘‘2003’’ and 
inserting ‘‘2009’’. 
(g) EFFECTIVE DATE AND LIMITATION FOR RULE 
RELATING
TO
TOLL-FREE
NUMBER
FOR
ADVERSE 
EVENTS ON LABELING FOR HUMAN DRUG PRODUCTS.— 
(1) IN GENERAL.—Notwithstanding subchapter 
II of chapter 5, and chapter 7, of title 5, United 
States Code (commonly known as the ‘‘Administra-
tive Procedure Act’’) and any other provision of law, 
the proposed rule issued by the Commissioner of 
Food and Drugs entitled ‘‘Toll-Free Number for Re-
porting Adverse Events on Labeling for Human 
Drug Products,’’ 69 Fed. Reg. 21778, (April 22, 
2004) shall take effect on January 1, 2008, unless 
such Commissioner issues the final rule before such 
date. 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00162
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
163 
(2) LIMITATION.—The proposed rule that takes 
effect under subsection (a), or the final rule de-
scribed under subsection (a), shall, notwithstanding 
section 17(a) of the Best Pharmaceuticals for Chil-
dren Act (21 U.S.C. 355b(a)), not apply to a drug— 
(A) for which an application is approved 
under section 505 of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 355); 
(B) that is not described under section 
503(b)(1) of such Act (21 U.S.C. 353(b)(1)); 
and 
(C) the packaging of which includes a toll- 
free number through which consumers can re-
port complaints to the manufacturer or dis-
tributor of the drug. 
TITLE VI—REAGAN-UDALL 
FOUNDATION 
SEC. 601. THE REAGAN-UDALL FOUNDATION FOR THE 
FOOD AND DRUG ADMINISTRATION. 
(a) IN GENERAL.—Chapter VII of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 371 et seq.) is amend-
ed by adding at the end the following: 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00163
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
164 
‘‘Subchapter I—Reagan-Udall Foundation for 
the Food and Drug Administration 
‘‘SEC. 770. ESTABLISHMENT AND FUNCTIONS OF THE FOUN-
DATION. 
‘‘(a) IN GENERAL.—A nonprofit corporation to be 
known as the Reagan-Udall Foundation for the Food and 
Drug Administration (referred to in this subchapter as the 
‘Foundation’) shall be established in accordance with this 
section. The Foundation shall be headed by an Executive 
Director, appointed by the members of the Board of Direc-
tors under subsection (e). The Foundation shall not be 
an agency or instrumentality of the United States Govern-
ment. 
‘‘(b) PURPOSE OF FOUNDATION.—The purpose of 
the Foundation is to advance the mission of the Food and 
Drug Administration to modernize medical, veterinary, 
food, food ingredient, and cosmetic product development, 
accelerate innovation, and enhance product safety. 
‘‘(c) DUTIES OF THE FOUNDATION.—The Founda-
tion shall— 
‘‘(1) taking into consideration the Critical Path 
reports and priorities published by the Food and 
Drug Administration, identify unmet needs in the 
development, manufacture, and evaluation of the 
safety and effectiveness, including postapproval, of 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00164
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
165 
devices, including diagnostics, biologics, and drugs, 
and the safety of food, food ingredients, and cos-
metics, and including the incorporation of more sen-
sitive and predictive tools and devices to measure 
safety; 
‘‘(2) establish goals and priorities in order to 
meet the unmet needs identified in paragraph (1); 
‘‘(3) in consultation with the Secretary, identify 
existing and proposed Federal intramural and extra-
mural research and development programs relating 
to the goals and priorities established under para-
graph (2), coordinate Foundation activities with 
such programs, and minimize Foundation duplica-
tion of existing efforts; 
‘‘(4) award grants to, or enter into contracts, 
memoranda of understanding, or cooperative agree-
ments with, scientists and entities, which may in-
clude the Food and Drug Administration, university 
consortia, public-private partnerships, institutions of 
higher education, entities described in section 
501(c)(3) of the Internal Revenue Code (and exempt 
from tax under section 501(a) of such Code), and 
industry, to efficiently and effectively advance the 
goals and priorities established under paragraph (2); 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00165
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS
166 
‘‘(5) recruit meeting participants and hold or 
sponsor (in whole or in part) meetings as appro-
priate to further the goals and priorities established 
under paragraph (2); 
‘‘(6) release and publish information and data 
and, to the extent practicable, license, distribute, 
and release material, reagents, and techniques to 
maximize, promote, and coordinate the availability of 
such material, reagents, and techniques for use by 
the Food and Drug Administration, nonprofit orga-
nizations, and academic and industrial researchers 
to further the goals and priorities established under 
paragraph (2); 
‘‘(7) ensure that— 
‘‘(A) action is taken as necessary to obtain 
patents for inventions developed by the Founda-
tion or with funds from the Foundation; 
‘‘(B) action is taken as necessary to enable 
the licensing of inventions developed by the 
Foundation or with funds from the Foundation; 
and 
‘‘(C) executed licenses, memoranda of un-
derstanding, material transfer agreements, con-
tracts, and other such instruments, promote, to 
the maximum extent practicable, the broadest 
VerDate Aug 31 2005 
05:37 Jul 12, 2007
Jkt 059200
PO 00000
Frm 00166
Fmt 6652
Sfmt 6201
E:\BILLS\H2900.RH
H2900
bajohnson on PROD1PC77 with BILLS